Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
← catalyst calendarNCT07732907 · readout in 5,459 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
15estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-04 | actual | When the study began enrolling |
| Primary completion | 2041-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2041-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Multiple Sclerosis
- Progressive Multifocal Leukoencephalopathy
Intervention
- Drug: Ozanimod
Primary outcome
what the primary-completion date above is the date OFProportion of progressive multifocal leukoencephalopathy (PML) cases by participant characteristics and potential risk factors among ozanimod-exposed participants with multiple sclerosis
measured Up to 15 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed